Apple Tree Partners’ latest cancer biotech company, Marengo Therapeutics, is using antibodies to selectively activate T cells to fight cancer. Led by former Merck KGaA executive Zhen Su, the startup is launching with $80 million in financing, which will support a drug pipeline that includes a lead program expected to reach the clinic in 2022.
